-
May 29, 2024 | 
pharmasalmanac.com | Nice Insight
Martinsried-Munich, Germany, May 29, 2024 – Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics and sterile drug product manufacturing support, announced the launch of a U.S. entity that allows customers to combine the convenience of a local service with the advantages of international expertise.
-
May 8, 2024 | 
pharmasalmanac.com | Nice Insight
Before initiating human trials for a pharmaceutical product, there is a crucial need to invest in chemistry, manufacturing, and controls (CMC) development to ensure the clinical product meets established quality manufacturing criteria. The main goal of CMC is to ensure the quality of the pharmaceutical product throughout its development stages.
-
May 2, 2024 | 
pharmasalmanac.com | Nice Insight
Philadelphia, PA – PCI Pharma Services, (“PCI”) a world leading global contract development and manufacturing organization (CDMO), has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus.
-
Mar 27, 2024 | 
pharmasalmanac.com | Nice Insight
Philadelphia, PA – PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report. A detailed overview of PCI’s multifaceted sustainability journey, the report showcases the strides taken from the program’s formal inception in 2021 through its 2023 fiscal year, and lays out ambitious goals for continued progress along multiple fronts.
-
Mar 13, 2024 | 
pharmasalmanac.com | Nice Insight
Menlo Park, CA and Milan, Italy – Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains and Olon Group, the global leader in developing and manufacturing active pharmaceutical ingredients (APIs) for CDMO (contract development and manufacturing organization) and generic markets, today announced an ongoing partnership to leverage Olon’s vast fermentation infrastructure to manufacture Antheia’s early products.
-
Mar 6, 2024 | 
pharmasalmanac.com | Nice Insight
FISHERS, IN. – March 6, 2024 – Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia (XLA) program.
-
Mar 5, 2024 | 
pharmasalmanac.com | Nice Insight
MINNEAPOLIS, MINN. – NMDPSM (formerly known as the National Marrow Donor Program), home to the most diverse blood stem cell and marrow donor registry in the world, announced the enrollment of the first patient in the groundbreaking OPTIMIZE clinical trial today. The trial is sponsored by NMDP through the Center for International Blood and Marrow Transplant Research (CIBMTR®).
-
Feb 21, 2024 | 
pharmasalmanac.com | Nice Insight
FISHERS, IN. and BOSTON, MA – Feb. 21, 2024 – Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary stable production system from biotechnology leader CSL. Cytegrity™ is an advanced inducible stable producer technology designed for the production of lentiviral vectors (LVVs).
-
Feb 8, 2024 | 
pharmasalmanac.com | Nice Insight
Although the druggable target universe continues to expand for biopharmaceutical developers, R&D costs are rising at a time when downward pricing pressures are also increasing, and expectations are heightened for measurably improved efficacy for new products compared with those already on the market. Being first to market with cost-effective, highly differentiated medicines is imperative to the success of not only the individual programs but the biopharma developers themselves.
-
Feb 5, 2024 | 
pharmasalmanac.com | Nice Insight
Milan, Italy - Olon Group announces the construction of a cutting-edge High Potency API suite. A GMP High Potency Active Pharmaceutical Ingredient (HPAPI) suite, currently under construction at the Olon USA site in Concord, Ohio, the center of excellence for early development of APIs within the Olon Group.
